News

FDA probes deaths of boys taking Sarepta Duchenne drug
The FDA said yesterday that it is investigating the deaths from liver failure of two non-ambulatory boys with Duchenne ...
Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny
FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety ...
Asianet Newsable on MSN7h
Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm
H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a ...
TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers.
Fierce Pharma11h
FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys
In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...
Fintel on MSN13h
HC Wainwright & Co. Downgrades Sarepta Therapeutics (SRPT)
Fintel reports that on June 25, 2025, HC Wainwright & Co. downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
1SRPT : Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts
The 12-month price targets, analyzed by analysts, offer insights with an average target of $72.34, a high estimate of $183.00 ...
Five things: Beth Israel DEI, Hao's successor, Sarepta investigation, and welcome back, Lucy
Here are the five things you need to know in Boston business news to start your busy workday, including Beth Israel's DEI shift, Hao's successor, Sarepta FDA investigation, and welcome back, Lucy CFO ...